These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Odevixibat: A Review of a Bioactive Compound for the Treatment of Pruritus Approved by the FDA. Porwal M; Kumar A; Rastogi V; Maheshwari KK; Verma A Curr Drug Res Rev; 2023 Mar; ():. PubMed ID: 36892028 [TBL] [Abstract][Full Text] [Related]
6. Maralixibat: First Approval. Shirley M Drugs; 2022 Jan; 82(1):71-76. PubMed ID: 34813049 [TBL] [Abstract][Full Text] [Related]
7. Odevixibat (Bylvay) for progressive familial intrahepatic cholestasis-associated pruritus. Med Lett Drugs Ther; 2022 Feb; 64(1644):28-29. PubMed ID: 35171896 [No Abstract] [Full Text] [Related]
8. Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial. Ovchinsky N; Aumar M; Baker A; Baumann U; Bufler P; Cananzi M; Czubkowski P; Durmaz Ö; Fischer R; Indolfi G; Karnsakul WW; Lacaille F; Lee WS; Maggiore G; Rosenthal P; Ruiz M; Sokal E; Sturm E; van der Woerd W; Verkade HJ; Wehrman A; Clemson C; Yu Q; Ni Q; Ruvido J; Manganaro S; Mattsson JP Lancet Gastroenterol Hepatol; 2024 Jul; 9(7):632-645. PubMed ID: 38670135 [TBL] [Abstract][Full Text] [Related]
9. Validation of the PRUCISION Instruments in Pediatric Patients with Progressive Familial Intrahepatic Cholestasis. Gwaltney C; Ivanescu C; Karlsson L; Warholic N; Kjems L; Horn P Adv Ther; 2022 Nov; 39(11):5105-5125. PubMed ID: 36066745 [TBL] [Abstract][Full Text] [Related]
10. Odevixibat: A Novel Bile Salt Inhibitor Treatment for Pruritus in Progressive Familial Intrahepatic Cholestasis. Flattmann FE; Mohiuddin FS; Singh A; Tandon A; Lockett SJ; Hirsch JD; Mosieri CN; Kaye AM; Varrassi G; Ahmadzadeh S; Shekoohi S; Kaye AD Cureus; 2024 Mar; 16(3):e56886. PubMed ID: 38659510 [TBL] [Abstract][Full Text] [Related]
11. Treatment with an ileal bile acid transporter inhibitor in patients with TJP2 deficiency. Di Giorgio A; Sciveres M; Fuoti M; Sonzogni A; Mandato C; D'Antiga L Clin Res Hepatol Gastroenterol; 2023 Oct; 47(8):102185. PubMed ID: 37499899 [TBL] [Abstract][Full Text] [Related]
12. Case Report: Add-on treatment with odevixibat in a new subtype of progressive familial intrahepatic cholestasis broadens the therapeutic horizon of genetic cholestasis. Pepe A; Colucci A; Carucci M; Nazzaro L; Bucci C; Ranucci G; Di Giorgio A; Vajro P; Mandato C Front Pediatr; 2023; 11():1061535. PubMed ID: 36865697 [TBL] [Abstract][Full Text] [Related]
13. Paediatric research sets new standards for therapy in paediatric and adult cholestasis. Jeyaraj R; Maher ER; Kelly D Lancet Child Adolesc Health; 2024 Jan; 8(1):75-84. PubMed ID: 38006895 [TBL] [Abstract][Full Text] [Related]
14. Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Karpen SJ; Kelly D; Mack C; Stein P Hepatol Int; 2020 Sep; 14(5):677-689. PubMed ID: 32653991 [TBL] [Abstract][Full Text] [Related]
15. Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis. Kamath BM; Stein P; Houwen RHJ; Verkade HJ Liver Int; 2020 Aug; 40(8):1812-1822. PubMed ID: 32492754 [TBL] [Abstract][Full Text] [Related]